Can I read TSID 10530 Pembrolizumab For Nasopharyngeal Cancer v1.0 JAN2021 NON CONF on EtoBox?

TSID 10530 Pembrolizumab For Nasopharyngeal Cancer v1.0 JAN2021 NON CONF by Pamela Chr is a document available to read on EtoBox.

What is TSID 10530 Pembrolizumab For Nasopharyngeal Cancer v1.0 JAN2021 NON CONF about?

Pembrolizumab is an immunotherapy drug currently in phase III clinical development for treating platinum pre-treated recurrent or metastatic nasopharyngeal cancer (NPC), a rare and often advanced-stage cancer. It enhances T-cell activity by blocking the PD-1 receptor, potentially offering a new treatment option for patients with limited current therapies. The drug is already licensed for various other cancer treatments in the UK, and its efficacy and safety are being evaluated in ongoing clinical trials.

Author

Pamela Chr

Language

EN